Document Type
Journal Article
Publication Title
Frontiers in Endocrinology
Volume
12
Publisher
Frontiers Media S. A.
School
School of Medical and Health Sciences / Institute for Nutrition Research
RAS ID
40596
Funders
Seeding Funds for Basic Research of the University of Hong Kong
Research Grant Council University Grants Committee NSFC-NHMRC
Joint Research Scheme National Heart Foundation of Australia
Abstract
Objectives:
To investigate the serum, plasma and urine levels of lipocalin-2 (LCN2) variants in healthy humans and their associations with risk factors for cardiometabolic (CMD) and chronic kidney (CKD) diseases.
Methods:
Fifty-nine males and 41 females participated in the study. Blood and urine were collected following an overnight fasting. LCN2 variants were analyzed using validated in-house ELISA kits. Heart rate, blood pressure, lipids profile, glucose, adiponectin, high-sensitivity C-reactive protein (hsCRP), creatinine, cystatin C, and biomarkers for kidney function were assessed.
Results:
The levels of hLcn2, C87A and R81E in serum and urine, but not plasma, were significantly higher in men than women. Increased levels of LCN2 variants, as well as their relative ratios, in serum and plasma were positively associated with body mass index, blood pressure, triglyceride and hsCRP (P < 0.05). No significant correlations were found between these measures and hLcn2, C87A or R81E in urine. However, LCN2 variants in urine, but not plasma or serum, were correlated with biomarkers of kidney function (P < 0.05).
Conclusions:
Both the serum and plasma levels of LCN2 variants, as well as their ratios are associated with increased cardiometabolic risk, whereas those in urine are correlated with renal dysfunction. LCN2 variants represent promising biomarkers for CMD and CKD.
DOI
10.3389/fendo.2021.781763
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Comments
Li, D., Li, H., Bauer, C., Hu, Y., Lewis, J. R., Xu, A., . . . Wang, Y. (2021). Lipocalin-2 variants and their relationship with cardio-renal risk factors. Frontiers in Endocrinology, 12, article 781763.
https://doi.org/10.3389/fendo.2021.781763